Gainplan’s Zosano Pharma Corporation ZSAN Stock Holding History

Gainplan’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-61	Closed	-$82K	–	17
2017 Q1	$82K	Buy	+61	New	+$73.6K	0.05%	11

Other funds holding ZSAN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gainplan's ZSAN Position: Q2 2017 in Review

Gainplan sold out of Zosano Pharma Corporation (ZSAN) in Q2 2017, closing a stake of 61 shares — an estimated $82K sold.

Gainplan first reported a position in ZSAN in Q1 2017 and held it in 1 quarter. The position peaked at $82K in Q1 2017. 26 funds tracked by Wall St. Rank hold ZSAN as of Q2 2017.

Gainplan reported no remaining Zosano Pharma Corporation position as of Q2 2017 after selling out during the quarter.
Gainplan sold 61 Zosano Pharma Corporation shares in Q2 2017, an estimated $82K.
Gainplan first reported a position in Zosano Pharma Corporation in Q1 2017 and held it in 1 quarter.
Gainplan's Zosano Pharma Corporation position peaked at $82K in Q1 2017.
26 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2017.

Based on Gainplan's 13F filing for Q2 2017, filed 2 Aug 2017.